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Background: MicroRNAs(miRNAs) are small non-coding RNAs that participate in a variety of biologic processes, and
dysregulation of miRNA is always associated with cancer development and progression. Aberrant expression of
miR-378 has been found in some types of cancer. However, effects and potential mechanisms of miR-378 in
colorectal cancer (CRC) have not been explored.
Methods: Quantitative RT-PCR was performed to evaluate miR-378 levels in CRC cell lines and 84 pairs of CRC
cancer and normal adjacent mucosa. Kaplan–Meier and Cox proportional regression analyses were utilized to
determine the association of miR-378 expression with survival of patients. MTT and invasion assays were used to
determine the role of miR-378 in regulation of CRC cancer cell growth and invasion, respectively. Tumor growth
was assessed by subcutaneous inoculation of cells into BALB/c nude mice. Luciferase assay was performed to assess
miR-378 binding to vimentin gene.
Results: In this study, we confirmed that miR-378 significantly down-regulated in CRC cancer tissues and cell lines.
Moreover, patients with low miR-378 expression had significantly poorer overall survival, and miR-378 expression
was an independent prognostic factor in CRC. Over-expression of miR-378 inhibited SW620 cell growth and
invasion, and resulted in down-regulation of vimentin expression. However, miR-378 knock-down promoted these
processes and enhanced the expression of vimentin. In addition, we further identified vimentin as the functional
downstream target of miR-378 by directly targeting the 3′-UTR of vimentin.
Conclusions: In conclusion, miR-378 may function as a tumor suppressor and plays an important role in inhibiting
tumor growth and invasion. Our present results implicate the potential effects of miR-378 on prognosis and treatment of
CRC cancer.
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Colorectal cancer (CRC) is one of the most common
malignancies worldwide, and it has high mortality and
prevalence rates in East Asian countries including China
[1]. Metastasis is the major cause of CRC morbidity and
mortality, and more than one-third of patients with CRC
will ultimately develop metastatic disease [2]. An urgent* Correspondence: zhoutong0088@163.com
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miRNAs are a class of small non-coding RNAs, which
contain of about 22 nucleotides. miRNAs bind to partially
complementary sequences in the 3`-untranslated region
(UTR) of specific target mRNA, resulting in either mRNA
degradation or translation inhibition [3]. Growing evidence
suggests that miRNAs play an important role in various
biologic processes, including cell proliferation, develop-
ment, and differentiation [4,5]. Furthermore, increasing
numbers of miRNAs have been observed in various types
of cancer and may be involved in modulating cancer cell
behaviors [6-9]. These data emphasize the importance ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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sights into understanding the molecular mechanism of
tumorigenesis.
Alterations in miRNA expression have been suggested
to play important roles in tumorigenesis and cancer pro-
gression [10]. Recently, miR-378 expression was shown
to be deregulated in oral carcinoma and renal cell car-
cinoma [11,12]. The involvement of miR-378 in the
tumorigenesis and metastasis of glioblastoma, non-small
cell lung cancer, breast cancer and gastric cancer has
also been reported [13-16]. Previous reports revealed
that the miR-378 was down-regulated in CRC [17-20].
However, to our knowledge, its biological role and clin-
ical significance in colorectal cancer remain undefined.
Therefore, in this study, we confirmed the expression
of miR-378 in fresh CRC tissue specimens and CRC cell
lines by using qRT-PCR. After that, we assessed the clin-
ical significance of miR-378 in colorectal cancer, and to
investigate the effects of miR-378 on CRC cells growth
and invasion and further discuss the mechanisms of ac-
tion of miR-378 by identifying its potential target gene.
Methods
Patients and tissue samples
Surgical specimens of cancer tissue and adjacent normal
mucosa were obtained from 86 patients with colorectal
cancer who underwent surgery at The Affiliated Hospital
of North Sichuan Medical College between 2005 and
2008. Among the 86 patients, 2 patients diagnosed with
distant metastases were excluded from our study be-
cause these cases were too few for meaningful statistical
analysis. None of the patients had received chemother-
apy or radiotherapy before surgery excision. After collec-
tion, all tissue samples were immediately frozen in liquid
nitrogen and stored at −80°C until use. Tumor stage was
classified according to the International Union against
Cancer (UICC, 6th ed., 2002). Informed written consent
was obtained from each patient, and research protocols
were approved by the Medical Ethics Committee of North
Sichuan Medical College.
Cell culture
The human CRC cell lines HT29, HCT116, SW480,
SW620 and the normal colon epithelium cell line CCD-
18Co were obtained from the American Type Culture
Collection and cultured in DMEM medium supple-
mented with 10% fetal bovine serum, 100u/ml penicillin
and 100 mg/ml streptomycin, at 37°C in a humidified at-
mosphere of 5% CO2.
RNA extraction and real-time RT–PCR
Total RNA was extracted using TRIzol reagent (Invitro-
gen, Carlsbad, CA, USA). The PCR primers for miR-378
and U6 were purchased from Applied Biosystems (ABI,Foster City, CA, USA). The PCR primers for vimentin were
5′-GAGAACTTTGCCGTTGAAGC-3′ and 5′-GCTTCC
TGTAGGTGGCAATC-3′. The primers for β-actin: 5′-CC
AAGGCCAAC CGCGAGAAGATGAC-3′ and 5′-AGGG
TACATGGTGGTGCCGCCA GAC-3′. The first-strand
cDNA was synthesized using the PrimeScript RT reagent
Kit (TaKaRa, Dalian, China). Real-time PCR was performed
using SYBR Premix Ex Taq (TaKaRa) and measured in a
LightCycler 480 system (Roche, Basel, Switzerland). U6
or β-actin was used as internal control. Relative quan-
tification of microRNA expression was calculated using
the 2-ΔΔCT method.Transfection of miRNA
The pre-miR miRNA-378(Pre-miR-378), pre-miR nega-
tive control (Pre- miR-nc), anti-miR negative control
(anti-miR-nc) and anti-miR-378 inhibitor (anti-miR-378)
were purchased from Ambion (Austin, TX,USA). 2 × 105
cells were seeded into each well of a 6-well plate and
transfected for 24 h or 48 h using Lipofectamine 2000
reagent (Invitrogen) following manufacturer’s protocol.
Transfected cells were used in further assays or RNA/
protein extraction.MTT assay
A total of 2 × 104 SW620 cells were plated onto 96-well
plates for 24 h. The cells were then transfected with 50
nM the indicated miRNA. At different time points
(24 h, 48 h and 72 h), the culture medium was removed
and replaced with culture medium containing 10 μl of
sterile MTT dye (5 mg/ml). After incubation at 37°C
for 4 h, the MTT solution was removed, and 150 μl
dimethyl sulfoxide (DMSO) was added to each well
followed by measuring the absorbance at 570 nm on an
enzyme immunoassay analyzer (Bio-Rad, Hercules,
CA, USA).Matrigel invasion assay
Cell invasion experiment was assessed using the Matri-
gel Invasion Chamber of pore size 8 mm (Corning
Costar Corporation, Cambridge, MA, USA). A total of
5 × 104 cells were seeded into the upper compartment
of the chamber coated with 150 μg of Matrigel (BD
Biosciences, Bedford, MD,USA). Medium containing
10% fetal bovine serum in the lower chamber served as
the chemoattractant. After the cells were incubated for
48 hours and fixed and stained with hematoxylin for
30 minutes, and the non-invaded cells were removed
with cotton swabs. The number of invasive cells on the
lower surface of the membrane was then counted under
a microscope at a magnification of × 400 in 5 random
fields.
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Female BALB/C nude mice at the age of 4 weeks pur-
chased from the Shanghai Laboratory Animal Center
(Chinese Academy of Sciences) were randomly divided
into 2 groups (five mice per group). All the procedures
involving animals were approved by Experimental Ani-
mal Ethics Committee, North Sichuan Medical College.
Pre-miR-378 or pre-miR-nc stable transfection SW620
cells suspensions (1 × 106 cells/ml) in 200 μl serum-free
medium were subcutaneously injected into the flanks of
nude mice, respectively. Tumor growth was examined
twice per week for 5 weeks and tumor volumes were
calculated using the formula Volume (mm3) = L × W2 /2
(length L, mm; width W, mm). After 5 weeks, tumor
samples were carefully removed and weighed.Western blot analysis
Immunoblotting was performed to detect the expres-
sion of vimentin in CRC cell lines. Transfected cells
were lysed in RIPA lysis buffer (ProMab Biotechnol-
ogy). Protein was loaded onto a SDS-PAGE minigel
and transferred onto PVDF membrane. After probed
with 1:500 diluted mouse anti-vimentin (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) at 4°C overnight, the
blots were subsequently incubated with HRP-conjugated
secondary antibody (1:5000). Signals were visualized using
ECL Substrates (Millipore, MA, USA). GAPDH was used
as an endogenous protein for normalization.Dual-luciferase reporter assay
For luciferase reporter experiments, the wild-type and
mutated 3′UTR of vimentin mRNA were subcloned
into the XhoI and NotI site of the psicheck-2 vector (Pro-
mega) and the new vectors were named psicheck-2-
vimentin-WT and psicheck-2-vimentin-MUT, respectively.
The following primers were used to amplify specific frag-
ments: vimentin-WT, forward 5′- CACAACTCGAGTTG
CACACACTCAGTG CAGC-3′ and reverse 5′- AAGG
AAAAAAGCGGCCGCCAAGTTGG TTGGATACTTGC
TGG-3′and vimentin-MUT, forward 5′- GTTTTAG TC
CTGCGCAAGATAGATTTGGAATAGGA-3′and Reverse
5′- TGC GCAGGACTAAAACTGCAGAAAGGCACTTG
AAAGCTG-3′. For reporter assay, HEK 293 T cells were
plated onto 24-well plates at 2 × 104 cells/well and
transfected with 200 ng of psicheck-2-wimentin-WT
or psicheck-2-vimentin-MUT and 40 nM pre-miR-378
or pre-miR-nc using Lipofectamine 2000 (Invitrogen).
Firefly luciferase was used to normalize the Renilla
luciferase. After transfection for 48 h, cells were har-
vested and assayed with Dual-Luciferase Reporter
Assay System (Promega) according to the manufac-
turer’s protocols.Statistical analysis
All data presented in this study have been repeated at
least three times from three independent experiments.
Continuous variables were expressed as the mean ±
standard deviation. The differences between groups were
analyzed using student’s t-test, while categorical data
were studied using chi-square test. The postoperative
survival rate was analyzed with Kaplan–Meier method,
and differences in survival rates were assessed with log-
rank test. A Cox proportional hazards model was used
for multivariate analysis. All statistical analyses were per-
formed using SPSS 16.0 software (SPSS, Chicago, IL,
USA). Two-sided P-values were calculated, and differ-
ences were considered significant at P-values of <0.05.
Results
The miR-378 expression in CRC tissues and cell lines
We performed quantitative PCR analysis to detect the
expression level of miR-378 in CRC tissues and cell
lines. In 84 cases of primary CRC tissues and their adja-
cent normal colonic tissues, our results showed that
miR-378 was significantly decreased in CRC tissues
(1.31 ± 0.57) when compared with that in the paired ad-
jacent normal tissues(2.82 ± 1.12) (P < 0.01, Figure 1A).
The expression of miR-378 was then assessed in four
CRC cell lines (SW620, SW480, HT29 and HCT116)
and the normal colon epithelium cell line CCD-18Co.
The results showed that the level of miR-378 was lower
in all four CRC cell lines compared with normal colon
cell line (Figure 1B).
Correlation between miR-378 expression and clinical
features and prognosis of CRC patients
To evaluate the correlation between miR-378 expression
and clinicopathological characteristics, the 84 patients
with CRC cancer were classified into two groups accord-
ing to the median expression (2.77) of miR-378. We
compared the clinicopathological factors of the high
and low miR-378 expression group (Table 1) and
found that low expression of miR-378 was significantly
correlated with large tumor size (P = 0.035), positive
lymph node metastasis (P = 0.004), and advanced clin-
ical stage (P = 0.017).
Kaplan–Meier survival analysis showed that low
miR-378 expression correlated with shorter overall
survival (Figure 2, P = 0.004). Univariate proportional
hazard model revealed a statistically significant correl-
ation between overall survival and miR-378 level,
tumour size, local invasion, lymph node metastasis,
and TNM stage (Table 2). The parameters that signifi-
cantly correlated with survival in the univariate ana-
lysis were further assessed by multivariate analysis.
Since TNM stage is determined by the local invasion
and lymph node metastasis, it was not further enrolled
Table 1 Association of miR-378 expression with
clinicopathologic factors of colorectal cancer patients
miR-378 expression
Variable Low (n = 42) High (n = 42) P-value
Age (years) 0.268
≤ 60 15 20





≤ 5 cm 24 33
> 5 cm 18 9
Histological grading 0.172
Well, moderate 24 30
Poor, mucinous 18 12










Lymph node metastasis 0.004
Negative 13 26
Positive 29 16
well: well-differentiated, moderate: moderately differentiated, poor: poorly
differentiated, mucinous: mucinous carcinoma.
Figure 1 The relative expression levels of miR-378 in CRC
tissues and cell lines. (A) The relative expression of miR-378 in
CRC tissues (T) and adjacent normal mucosa (N). The bars in the
figure indicate the means of the relative expressions of miR-378.
(B) The relative expression of miR-378 in CRC cell lines SW620,
SW480, HCT116, HT29 and the normal colon epithelium cell line
CCD-18Co. **P < 0.01.
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sults of the multivariate analysis demonstrated that
miR-378 (P = 0.037) and lymph node metastasis (P =
0.001) were independent prognostic factors for overall
survival (Table 2). These results indicated that miR-
378 may be involved in the progression of CRC and
predict overall survival in CRC.
Effect of miR-378 on CRC cell growth and invasion in vitro
To validate if miR-378 regulates CRC cell growth, we
performed a proliferation assay by transfecting pre-miR-
378 or pre-miR-nc into SW620 cells. It showed that the
increased expression of miR-378 induced significant in-
hibition on cell proliferation (Figure 3A). Correspond-
ingly, after transfected with anti-miR-378, SW620 cells
presented stimulated cell growth compared to scramblecontrol (Figure 3C). Cell motility of transfected cells was
evaluated by invasion assay. As shown in Figure 3B,
compared to the scramble control, pre-miR-378 trans-
fected SW620 cells exhibited significant impairment of
invasive ability. Inversely, down-regulation of miR-378 in
inhibitors transfected SW620 cells apparently promoted
cell invasion (Figure 3D).
MiR-378 inhibits tumor growth in vivo
To examine the role of miR-378 in CRC tumor develop-
ment, we used a BALB/C nude xenograft mouse model
in which mice were transplanted with pre-miR-378 and
pre-miR-nc transfected cells. After 5 weeks, miR-378
over-expressing tumors were significantly smaller than
those of mice transfected with scramble control (Figure 4A).
Furthermore, overexpression of miR-378 significantly
reduced xenograft tumor volume (Figure 4B) and tumor
weight (Figure 4C).
Figure 2 Kaplan–Meier survival curves of patients with colorectal cancer based on miR-378 expression status. Patients in the low
expression group had significantly poorer prognosis than those in high expression group (P = 0.004, log-rank test).
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To understand the possible mechanisms that might
underlie miR-378-mediated growth and metastasis sup-
pression, we performed in silico studies to search for po-
tential gene targets of miR-378 using the bioinformatics
algorithms Pictar and miRanda. All of the algorithms
indicated that vimentin was a theoretical target of miR-
378 (Figure 5A).
To further confirm that vimentin is the direct target of
miR-378, we first determined whether over-expression
of miR-378 can lead to down-regulation of vimentin ex-
pression. We transfected SW620 cells with pre-miR-378Table 2 Univariate and multivariate analyses of prognostic fa
Variable Univariate analysis
HR 95% CI
Age (years) 1.619 0.759-3.454
Gender 1.121 0.521-2.422
Location 1.691 0.783-3.652
Histological grading 1.844 0.861-3.949
Tumor size 2.414 1.123-5.186
Depth of invasion 2.374 1.083-5.202
Lymph node metastasis 5.286 1.996-13.999
Clinicopathological staging 2.863 1.268-6.564
MiR-378 3.165 1.381-7.253
HR: hazard ratio, CI: confidence interval.or anti-miR-378, Western blot showed that the en-
hanced miR-378 expression in SW620 cells significantly
repressed vimentin protein expression compared to cells
transfected with scramble control (Figure 5B). Relatively,
down-regulation of miR-378 by inhibitors in SW620
cells led to a moderate increase of vimenin protein level
(Figure 5B). Meanwhile, apparent alterations of vimentin
mRNA expression were also observed by quantitative
PCR (P < 0.01, Figure 5B). It suggested a potential regu-
lation of vimentin by miR-378. Thus, vimentin is likely
to be suppressed by miR-378 through translational in-
hibition and mRNA degradation.ctors in colorectal cancer
Multivariate analysis





0.024 2.086 0.954-4.563 0.066
0.031 1.461 0.650-3.282 0.358
0.001 5.080 1.940-13.554 0.001
0.013
0.006 2.492 1.057-5.876 0.037
Figure 3 Effects of miR-378 on proliferation and invasion of SW620 cell line. (A) (B) Over-expression of miR-378 inhibited SW620 cell
growth and invasion. (C) (D) Down-regulation of miR-378 promoted SW620 cell growth and invasion. *P < 0.05, **P < 0.01.
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UTR of target mRNA, we generated a luciferase reporter
vector that contain the vimentin 3′-UTR with the puta-
tive miR-378 binding sites. Correspondingly, we also
generated a mutant reporter vector which contains the
vimentin 3′-UTR with a mutation at the putative miR-
378 binding site (Figure 5A). As shown in Figure 5C, we
observed a marked reduction in luciferase activity in
cells transfected with pre-miR-378 compared with pre-
miR-nc transfected cells (P < 0.01). In contrast, no
change of luciferase was observed in cells transfected
with the mutant 3′-UTR constructs. Taken together,
these findings indicate that vimentin is a direct, down-
stream target for miR-378 in SW620 cells.Discussion
Several groups have screened for colon cancer-related
miRNAs, but limited evidence exists that causally link
specific miRNAs to specific functions [21]. Identification
of cancer-specific miRNAs and their targets is critical
for understanding their roles in tumorigenesis, and maybe important for finding out novel prognostic and thera-
peutic targets.
Accumulating evidence showed that up-regulation
of miR-378 was associated with several types of
human malignant solid tumors, including those of the
glioblastoma, breast cancer and renal cell carcinoma
[12,13,15]. In these types of cancer, miR-378 seemed
to be an oncogene, and enhanced tumor cell sur-
vival, promoted tumor growth and metastasis in
some tumors via regulation of the target genes SuFu,
Fus-1, HMOX1, ESRRG and GABPA [12-15]. However,
other studies demonstrated that miR-378 was down-
regulated in gastric cancer and oral cancer [11,16], and
miR-378 may act as tumor suppressors in gastric can-
cer by negatively regulating the expression of CDK6
and VEGF [16]. Therefore, the function of miR-378 is
complicated because it can be oncogenic or a tumor
suppressor in different types of cancers. Several studies
have been reported that miR-378 was significantly
down-regulated in CRC [17-20]. However, the specific
mechanism by which the altered expression of miR-
378 affects tumor development and progression has
Figure 4 MiR-378 inhibits tumor growth in vivo. (A) Representative image of tumors formed. (B) Growth curve drawn by measuring tumor
volumes at the indicated times. (C) Weight of xenograft tumors. **P < 0.01.
Zhang et al. BMC Cancer 2014, 14:109 Page 7 of 9
http://www.biomedcentral.com/1471-2407/14/109not been elucidated and its involvement in CRC has
not been addressed in detail.
In the current study, we further confirmed that miR-
378 expression was significantly down-regulated in CRC
tissue samples and cell lines, and that loss of miR-378 ex-
pression was associated with large tumor size, advanced
clinical stage, lymph node metastasis and shorter overall
survival of the patients with CRC, indicating that miR-378
might be involved in CRC progression and could be used
as a potential prognostic biomarker in CRC. Furthermore,
over-expression of miR-378 could significantly inhibit cell
proliferation and invasion in vitro and tumor growth
in vivo. On the contrary, when transfected with miR-378
inhibitors, SW620 cells exhibited stimulated proliferation
as well as invasive capabilities. This study first showed that
miR-378 may function as a tumor suppressor in CRC.
To explore the mechanisms underlying the inhibition
of CRC cell growth and invasion mediated by miR-378,
we next set out to identify the potential target genes
of miR-378. The bioinformatics analysis indicates that
vimentin may be the potential target for miR-378. One
of the key molecular steps in the process of distant
metastasis includes epithelial-to-mesenchymal transition
(EMT) [22], which permits invasion and migration inCRC [23], and is associated with a poor prognosis in
CRC [24]. The intermediate filament protein (IFP)
vimentin, expressed in mesenchymal cells, is a well-
known marker for EMT [25]. Vimentin expression and
perturbation of E-cadherin-mediated cell adhesion
are therefore both regarded as hallmarks of EMT-
associated events [26]. A recent report showed that
vimentin was one of the predominant overexpressed
proteins in the highly metastatic cell line SW620 [27].
Thus, in the present study, SW620 cells were selected
as model systems for the study of the molecular events
involved in CRC metastasis. A previous study sug-
gested that vimentin methylation was associated with
liver metastasis and peritoneal dissemination in colorectal
cancer [28]. Vimentin was also reported to be highly
expressed in CRC, and high expression of vimentin was
found to be associated with lymph node metastasis and dis-
ease recurrence in CRC [29,30].
Several pieces of evidence in our study indicate that
vimentin is a direct target gene of miR-378 in CRC cancer.
Firstly, at both mRNA and protein level, up-regulation of
miR-378 expression in SW620 cells effectively suppressed
vimentin expression, whereas, downregulation of miR-378
moderately promoted vimentin expression. It suggested a
Figure 5 Vimentin is a direct target of miR-378. (A) The wild-type (WT) and mutated (MUT) 3′UTR of vimentin, with the seed region and base
substitutions (bold). (B) The expression levels of vimentin mRNA and protein were detected by qRT-PCR and western blot assays. (C) Ectopic
miR-378 expression inhibits wild-type but not mutant vimentin 3′UTR reporter activity. *P < 0.05, **P < 0.01.
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CRC. Secondly, over-expression of miR-378 significantly re-
duces the activity of a luciferase reporter containing the 3′
UTR sequence of vimentin. In addition, vimentin has been
confirmed as a target gene of miR-378 in glioblastoma Cells
[30]. When combined with bioinformatic analysis, we con-
cluded vimentin was a target gene of miR-378 in CRC.
Taken together, these findings sufficiently consolidated that
miR-378 played a suppressive role in cellular proliferation
and invasion, at least, in part due to directly inhibiting
vimentin expression.Conclusion
In summary, our present study showed that miR-378
was down- regulated in CRC tissues and cell lines. And
the low expression pattern was observed to be signifi-
cantly correlated with increased tumor size, advanced
clinical stage, lymph node metastasis and worse prog-
nosis. We also found that miR-378 can inhibit tumor
growth and invasion partly by targeting vimentin. Ourdata implicated the potential application of miR-378 as
a tumor suppressor in CRC therapy and also as a
tumor marker for predicting prognosis.
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